The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While ...

Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...

Suzetrigine (Journavx) shows promise as a non-addictive pain treatment, offering systemic relief without opioid-related side effects, but faces Tier 3 insurance hurdles. Financially strong with a ...

Health system pharmacists and physicians are monitoring a wave of expected new drug approvals between late 2024 and third quarter of 2025. A recent article published in the American Journal of ...

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals' (NASDAQ:VRTX) non-opioid pain medicine Journavx (suzetrigine).

On 30 January 2025, the US Food and Drug Administration (FDA) approved the non-opioid medication suzetrigine (JOURNAVX), which was developed by Vertex Pharmaceuticals for moderate to severe acute ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

BB Biotech reported a net loss of CHF 241 mn for Q1 2025. The share price closed the quarter at a 14.1% discount to NAV, broadly in line with year-end 2024. The share price performance for the quarter ...

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains ...

UMass Lowell Recognized as Top Research Institution with R1 Classification Read More ⁠ ...